malaria
african
sleep
sick
human
african
trypanosomiasi
caus
parasit
protozoa
plasmodium
falciparum
trypanosoma
brucei
respect
among
sever
tropic
diseas
repres
major
health
issu
develop
world
approxim
million
malaria
infect
million
death
regist
annual
clinic
case
attribut
p
falciparum
concentr
within
african
region
human
african
trypanosomiasi
threaten
million
peopl
subsaharan
countri
africa
estim
annual
number
case
annual
mortal
close
emerg
multidrugresist
parasit
strain
addit
limit
avail
chemotherapi
demand
urgent
develop
new
effect
drug
novel
mechan
action
p
falciparum
brucei
offer
sever
potenti
target
enzym
implic
pathogenesi
host
cell
invas
includ
number
essenti
close
relat
cystein
proteas
largest
subfamili
among
papainlik
cystein
proteas
clan
ca
famili
p
falciparum
variou
proteas
catalyz
degrad
human
hemoglobin
provid
nutrient
exponenti
growth
matur
pathogen
hemoglobin
catabol
initi
seri
aspart
proteas
plasmepsin
histoaspart
proteas
perform
first
proteolyt
cleavag
degrad
smaller
peptid
fragment
achiev
uniqu
foodvacuol
cystein
proteas
falcipain
biolog
studi
reveal
overlap
activ
profil
plasmepsin
falcipain
conclud
plasmepsin
process
activ
falcipain
catabol
process
vital
specif
parasit
surviv
inhibit
falcipain
proven
indispens
order
complet
block
parasit
growth
prolifer
key
hemoglobinas
erythrocyt
parasit
abund
beststudi
enzym
emerg
promis
target
develop
novel
drug
bloodstream
brucei
rhodesiens
parasit
express
cystein
proteas
rhodesain
cathepsin
llike
hydrolas
rhodesain
involv
degrad
parasit
intracellularli
transport
host
protein
respons
gener
proteolyt
activ
life
stage
organ
cystein
proteas
inhibitor
shown
kill
african
trypanosom
vitro
anim
model
variou
type
rhodesain
inhibitor
develop
last
year
mainli
base
screen
method
howev
felt
expertis
structurebas
design
would
enabl
us
obtain
new
potent
select
inhibitor
without
need
screen
began
investig
base
first
xray
crystal
structur
avail
sinc
protein
data
bank
pdb
code
rhodesain
publish
recent
pdb
code
rhodesain
share
common
featur
clan
ca
cystein
proteas
classic
papain
fold
consist
two
distinct
domain
superimposit
structur
enzym
reveal
high
degre
analog
overal
fold
highest
conserv
observ
catalyt
domain
figur
sequenc
align
catalyt
domain
result
assign
enzym
cathepsin
llike
subfamili
structur
catalyt
dyad
cy
rhodesain
cy
embed
channellik
junction
two
domain
highli
conserv
peptid
sequenc
figur
b
activ
site
extend
apolar
pocket
strong
prefer
hydrophob
substitu
previou
work
suggest
pocket
key
determin
substrat
specif
papainlik
cystein
proteas
gener
structur
cystein
proteas
inhibitor
contain
preval
electrophil
moieti
form
revers
coval
thioimid
intermedi
catalyt
cystein
opt
specif
inhibitor
featur
nitril
residu
electrophil
head
group
nitrilecontain
pharmaceut
prescrib
varieti
medicin
indic
sever
clinic
develop
unsurprisingli
nitril
well
establish
class
cystein
proteas
inhibitor
oballa
et
al
hypothes
increas
electrophil
nitril
moieti
could
impact
revers
enzymeinhibitor
complex
format
accord
calcul
reactiv
aryl
nitril
particularli
pyrimidin
triazin
nitril
possess
reactiv
nitril
moieti
herein
describ
structurebas
design
effici
synthesi
biolog
evalu
new
seri
triazin
nitril
inhibitor
explor
bind
properti
rhodesain
guid
molecular
model
propos
bind
model
show
accommod
differ
vector
apolar
pocket
activ
site
inhibitor
test
close
relat
human
viral
cystein
proteas
well
serin
proteas
investig
gener
select
addit
vitro
activ
p
falciparum
brucei
rhodesiens
parasit
cytotox
studi
computeraid
model
use
mab
forc
field
within
moloc
appli
design
small
druglik
molecul
occupi
activ
site
identifi
diaminosubstitut
triazin
suitabl
central
scaffold
posit
vector
bind
pocket
direct
thioimid
adduct
stabil
oxyanion
hole
figur
occup
variou
pocket
figur
b
subsequ
optim
gain
high
bind
potenc
activ
site
analysi
model
reveal
morpholin
residu
could
act
suitabl
substitu
address
flat
predominantli
solventexpos
pocket
occup
larg
mainli
hydrophob
pocket
identifi
npropyl
cyclohexyl
substitu
optim
vector
undergo
sever
hydrophob
interact
side
chain
leu
ile
ser
reach
wide
pocket
moieti
chosen
stack
amid
backbon
gli
gli
figur
show
propos
bind
mode
lead
compound
activ
site
prepar
seri
function
triazin
nitril
inhibitor
vari
substitu
synthesi
inhibitor
shown
scheme
reduct
amin
keton
amin
gave
secondari
amin
good
yield
amin
subsequ
transform
deriv
reaction
equimolar
amount
cyanur
chlorid
n
ndiisopropylethylamin
ipr
net
introduct
second
vector
achiev
subsequ
nucleophil
aromat
substitut
morpholin
basic
condit
give
cyanat
use
potassium
cyanid
dimethyl
sulfoxid
high
temperatur
afford
ligand
compound
access
similar
rout
addit
effici
wwwchemmedchemorg
onepot
procedur
two
nucleophil
chlorin
substitut
step
develop
compound
detail
experiment
procedur
see
support
inform
singl
crystal
suitabl
xray
analysi
obtain
inhibitor
figur
support
inform
confirm
constitut
favor
structur
organ
compound
compound
test
p
falciparum
rhodesain
brucei
rhodesiens
tabl
respect
standard
fluorescencebas
assay
see
support
inform
investig
substitu
mostli
solventexpos
pocket
reveal
prefer
initi
design
morpholin
group
wherea
cyclopropylamin
deriv
prove
inact
replac
morpholin
vector
result
signific
chang
inhibitori
constant
k
ae
nm
k
ae
nm
affin
initi
design
activ
compound
k
ae
nm
consider
enhanc
omit
npropyl
substitu
compound
unsubstitut
cyclohexyl
moieti
significantli
potent
k
ae
nm
introduct
bulkier
group
result
loss
affin
three
order
magnitud
k
ae
nm
bind
affin
greatli
enhanc
decreas
size
pocket
vector
order
adamantyl
k
ae
nm
npropyl
cyclohexyl
k
ae
nm
cyclohexyl
k
ae
nm
furthermor
phenyl
ring
also
found
suitabl
substitut
pocket
phenylsubstitut
ligand
yield
activ
low
nanomolar
rang
k
ae
nm
k
ae
nm
k
ae
nm
data
emphas
import
proper
occup
pocket
previous
report
variat
substitu
wide
pocket
reveal
prefer
cyclohexyl
substitu
k
ae
nm
k
ae
nm
replac
moieti
trifluoromethyl
benzyl
residu
result
complet
loss
activ
compound
introduct
smaller
ethyl
isopropyl
substitu
led
inhibitori
constant
doubledigit
nanomolar
rang
k
ae
nm
k
ae
nm
inhibitori
constant
compound
also
assess
rhodesain
brucei
rhodesiens
lead
compound
unsubstitut
cyclohexyl
analogu
exhibit
highest
affin
seri
k
valu
ae
nm
ae
nm
respect
gener
activ
rhodesain
correl
well
howev
notabl
differ
observ
regard
occup
pocket
triazin
moder
activ
inact
rhodesain
suggest
less
extend
pocket
within
latter
enzym
importantli
two
enzym
differ
bottom
pocket
strong
prefer
shorter
cyclohexyl
substitu
k
ae
nm
npropyl
cyclohexyl
k
ae
nm
display
k
valu
rhodesain
singledigit
nanomolar
rang
k
ae
nm
nm
model
suggest
bottom
pocket
line
ile
asp
narrow
polar
compar
region
rhodesain
line
met
ala
see
figur
support
inform
competit
inhibit
confirm
determin
appar
dissoci
constant
rhodesain
inhibit
compound
variou
substrat
concentr
reveal
linear
relationship
appar
dissoci
constant
substrat
concentr
result
presum
assign
whole
seri
order
studi
gener
select
synthes
inhibitor
relat
cystein
proteas
compound
test
human
cathepsin
b
cathepsin
l
sever
acut
respiratori
syndromecoronaviru
sarscov
papainlik
proteas
main
proteas
tabl
support
inform
superimposit
select
amino
acid
activ
site
cathepsin
b
cathepsin
l
emphas
structur
similar
see
figur
support
inform
compound
show
affin
human
cathepsin
l
low
nanomolar
rang
wherea
moder
good
select
enzym
observ
deriv
moreov
compound
highli
select
human
cathepsin
b
viral
cystein
proteas
furthermor
compound
inact
achymotrypsin
reveal
select
cystein
serin
proteas
newli
synthes
compound
test
abil
inhibit
growth
malaria
parasit
p
falciparum
trypanosomatid
brucei
rhodesiens
vitro
tabl
nitril
exhibit
moder
activ
p
falciparum
ic
valu
mm
ic
valu
brucei
rhodesiens
trypomastigot
rang
mm
mm
compar
data
obtain
assay
brucei
brucei
strain
data
shown
correl
inhibit
parasit
cystein
proteas
vitro
activ
could
establish
might
due
offtarget
effect
physic
chemic
prop
wwwchemmedchemorg
erti
compound
gener
cytotox
effect
indic
cytotox
observ
rat
myoblast
cell
tabl
human
macrophag
data
shown
lead
low
select
indic
investig
current
ongo
improv
vitro
select
compound
conclus
design
synthes
small
librari
potent
select
competit
inhibitor
protozoan
cystein
proteas
rhodesain
promis
inhibitori
activ
k
ae
nm
k
ae
nm
rhodesain
obtain
first
gener
triazin
nitrilebas
ligand
major
differ
two
close
relat
enzym
observ
optim
occup
pocket
appear
narrow
polar
compar
rhodesain
biolog
assay
show
case
good
select
close
relat
human
cathepsin
l
overal
high
select
cathepsin
b
viral
cystein
proteas
achymotrypsin
contrast
excel
enzymat
activ
good
select
vitro
studi
reveal
moder
activ
major
synthes
compound
p
falciparum
margin
activ
brucei
rhodesiens
studi
necessari
explor
extent
inhibitor
reach
actual
biolog
target
order
understand
low
activ
cellbas
assay
